NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

The statistically manipulated primary endpoint WON'T play well with the FDA (correction).
Double dosing treatment arm but compare to external trials that don't raises several issues.
Do you try to claim the "statistical manipulation" of the primary endpoint and try to claim no clinical advantage for DCVax-L double dosing vs. comparators that weren't screened for double dosing, .